SAB Biotherapeutics (NASDAQ:SABS) Issues Quarterly Earnings Results, Misses Estimates By $0.15 EPS

SAB Biotherapeutics (NASDAQ:SABS) announced its quarterly earnings results on Tuesday. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SABBio said SAFEGUARD enrollment is on track, with Part A fully enrolled and Part B now actively enrolling across the U.S., Australia, New Zealand, the U.K. and Europe.
• The company received FDA written confirmation that C-peptide may be used as a surrogate endpoint for accelerated approval, which management described as a meaningful de-risking of the regulatory path.
• Phase I SAB-142 data continued to support the program, with management highlighting beta-cell preservation, T-cell exhaustion, and a favorable safety profile including no serum sickness and low or no immunogenicity.
• SABBio ended Q1 with $217.6 million in cash, cash equivalents and available-for-sale securities, which it says funds operations through 2028 and supports SAFEGUARD plus pre-commercial work.
• The company also signed a multi-year manufacturing agreement with Emergent BioSolutions to support process development and both clinical and commercial production ahead of a potential launch.

SAB Biotherapeutics Price Performance

Shares of SABS stock traded up $0.19 during trading hours on Wednesday, hitting $3.81. 199,583 shares of the company’s stock were exchanged, compared to its average volume of 646,356. The stock’s 50-day moving average is $3.86 and its 200-day moving average is $3.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. SAB Biotherapeutics has a 52 week low of $1.60 and a 52 week high of $6.60. The stock has a market cap of $194.07 million, a price-to-earnings ratio of -1.64 and a beta of 0.55.

Wall Street Analysts Forecast Growth

SABS has been the subject of several analyst reports. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Chardan Capital lifted their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. HC Wainwright upped their target price on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Friday, April 10th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, SAB Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SABS. Dimensional Fund Advisors LP bought a new position in SAB Biotherapeutics in the 3rd quarter valued at $32,000. ADAR1 Capital Management LLC bought a new stake in shares of SAB Biotherapeutics during the third quarter worth $30,000. Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics during the third quarter worth $40,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics during the 3rd quarter valued at about $8,847,000. Finally, Vivo Capital LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at approximately $22,954,000. Institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.